Poster SESSIONS
75
Poster, 25 June 2014
Authors are asked to present their posters during the poster sessions.
P-43-015
Tolerability and safety profile of aripiprazole
once-monthly in the treatment of schizo-
phrenia: A pooled analysis from the safety
database of 11 completed or ongoing trials
Anna-Greta Nylander, Valby, Denmark
R. A. Baker, P. Hertel, N. Jin, A. Eramo, R. Duffy,
R. D. McQuade, T. Peters-Strickland
P-43-016
The effect of previous dose of oral aripipra-
zole (10 or 30mg/day) on the efficacy and
tolerability of aripiprazole once-monthly:
Post-hoc analysis of two double-blind, ran-
domized, controlled trials
Anna-Greta Nylander, Valby, Denmark
A. Eramo, R. Baker, L.-F. Tsai, T. Peters-Strick-
land, R. Sanchez
P-43-017
Defects of neurocognitive performance and
social functioning in non-prodromal indi-
viduals with high genetic loading for schizo-
phrenia
Jin Woo Park, Seoul, Republic of Korea
S. N. Kim, T. Y. Lee, C. Lee, Y. S. Shin, J. S. Kwon,
D.-H. Kang, J. H. Jang, N. Y. Shin
P-43-018
The change of polyunsaturated fatty acid
(PUFA) concentration during paliperidone
extended-release treatment and the plasma
concentration of paliperidone ER at week-2
and week-3
Jong-Il Park, Jeonju, Republic of Korea
Y.-C. Chung, B.-J. Lee, S.-H. Lee, S. J. Lee,
J.-I. Park, B. Nam, T. Sumiyoshi
P-43-019
Convergence of clozapine induced ErbB1-
ERK and ErbB4-PI3K/AKT signalling in
prefrontal cortical neurons: Relevance to
therapeutic efficacy
Avril Pereira, Melbourne, Australia
Y.-S. An, R. Sethi, P. Malcolm, S. Sundram
P-43-020
Efficacy and tolerability of paliperidone pal-
mitate long-acting injectable antipsychotic in
first-episode schizophrenic patients
Daniela Petric, Rijeka, Croatia
V. Racki, M. Graovac, A. Kastelan, T. Grahovac,
M. Vucic-Peitl, T. Franciskovic
P-43-021
A mirror-image study to compare the effi-
ciency of paliperidone palmitate with oral
antipsychotics in schizophrenic patients
Philippe Vincent, Montreal, Canada
P-43-022
Prefrontal GABA-blockade and decision mak-
ing: Relevance for schizophrenia
Patrick Piantadosi, Vancouver, Canada
S. Khayambashi, A. Cywinska, M. Schluter,
S. Floresco
P-43-023
Extracellular matrix metabolism was un-
veiled in physiophology of schizophrenia
by interacted genome-wide association study
and consequent downstream analysis
Hongyan Ren, Chengdu, China
P-43-024
Efficacy of lurasidone in the treatment of
schizophrenia with prominent negative
symptoms: A post-hoc analysis of short-
term trials
Nina R. Schooler, Brooklyn, USA
A. Pikalov, J. Hsu, J. Cucchiaro, R. Goldman,
A. Loebel
P-43-025
Pitfall of using absolute Framingham Risk
Score for primary prevention strategy in
schizophrenia
Cynthia Siu, Flemington, USA
C. Brambilla
P-43-027
Inhaled loxapine and intramuscular loraz-
epam in healthy volunteers: Results of a
randomized, placebo-controlled drug-drug
interaction study
Daniel A Spyker, Mountain View, Ca, USA
J. V. Cassella, R. R. Stoltz, P. P. Yeung
P-43-028
Quality of life and first episode of schizo-
phrenia
Iva Stehnova, Brno, Czech Republic
M. Sisrova, L. Ustohal, M. Mayerova, D. Be-
rankova
P-43-029
Cognition and schizophrenia: Neuropsycho-
logical profile, dynamics, psychopathology
and pharmacotherapy
Iva Stehnova, Brno, Czech Republic
M. Sisrova, L. Ustohal, M. Mayerova, D. Be-
rankova
